Literature DB >> 9543648

Adolescent versus adult onset and the development of substance use disorders in males.

D B Clark1, L Kirisci, R E Tarter.   

Abstract

This study examines the influence of adolescent age of onset on the development of substance use disorders (SUD) by comparing adult males (n = 181) with SUD categorized into adolescent-onset, early-adult onset and late-adult onset groups on patterns of substance use and related disorders, time course of the development of substance dependence and rates of comorbid mental disorders. A sample of male adolescents (n = 81) with SUD was also included as a comparison group. The subjects were recruited from intervention programs in the community and participated in semistructured interviews with diagnoses determined by the best estimate method. Adolescent-onset adults, compared with other adult-onset groups, had higher lifetime rates of cannabis and hallucinogen use disorders, shorter times from first exposure to dependence, shorter times between the development of their first and second dependence diagnoses and higher rates of disruptive behavior disorders and major depression. Adolescents were similar to adolescent-onset adults. While the findings must be interpreted in light of methodological limitations, these results suggest that adolescent-onset SUD is a distinct subtype involving different substances and more rapid development than adult-onset SUD.

Entities:  

Mesh:

Year:  1998        PMID: 9543648     DOI: 10.1016/s0376-8716(97)00154-3

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  81 in total

1.  Psychostimulant dependence in a community sample.

Authors:  Li-Tzy Wu; William E Schlenger
Journal:  Subst Use Misuse       Date:  2003-01       Impact factor: 2.164

2.  Effects of periadolescent versus adult cocaine exposure on cocaine conditioned place preference and motor sensitization in mice.

Authors:  Nicole L Schramm-Sapyta; Adeola R Pratt; Danny G Winder
Journal:  Psychopharmacology (Berl)       Date:  2004-01-08       Impact factor: 4.530

3.  Escalation of methamphetamine self-administration in adolescent and adult rats.

Authors:  Justin J Anker; Thomas R Baron; Natalie E Zlebnik; Marilyn E Carroll
Journal:  Drug Alcohol Depend       Date:  2012-02-02       Impact factor: 4.492

Review 4.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

5.  Adolescent rats are protected from the conditioned aversive properties of cocaine and lithium chloride.

Authors:  Nicole L Schramm-Sapyta; Richard W Morris; Cynthia M Kuhn
Journal:  Pharmacol Biochem Behav       Date:  2006-07-03       Impact factor: 3.533

6.  Identifying childhood characteristics that underlie premorbid risk for substance use disorders: socialization and boldness.

Authors:  Brian M Hicks; William G Iacono; Matt McGue
Journal:  Dev Psychopathol       Date:  2013-11-26

7.  Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine.

Authors:  Megan J Shram; Douglas Funk; Zhaoxia Li; Anh D Lê
Journal:  Psychopharmacology (Berl)       Date:  2006-04-04       Impact factor: 4.530

Review 8.  Alcohol use disorders in adolescents: epidemiology, diagnosis, psychosocial interventions, and pharmacological treatment.

Authors:  Duncan B Clark; Oscar Bukstein; Jack Cornelius
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

9.  A new definition of early age at onset in alcohol dependence.

Authors:  Yann Le Strat; Bridget F Grant; Nicolas Ramoz; Philip Gorwood
Journal:  Drug Alcohol Depend       Date:  2009-12-16       Impact factor: 4.492

Review 10.  The emergence of gonadal hormone influences on dopaminergic function during puberty.

Authors:  Cynthia Kuhn; Misha Johnson; Alex Thomae; Brooke Luo; Sidney A Simon; Guiying Zhou; Q David Walker
Journal:  Horm Behav       Date:  2009-11-10       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.